Early detection of cervical cancer can reduce mortality to a great extent. Unlike most other types of cancer, cervical cancer is preventable when precursor lesions are detected and treated early. Cervical cancer is totally avoidable not only because the definitive cause of cervical cancer is now known, but also because the disease takes a longer time to develop after initial infection with high-risk Human papillomavirus (HPV) in most cases. Screening can significantly reduce both the incidence and mortality of cervical cancer.

It is estimated that over 311,000 women globally die from cervical cancer every year and nearly 84% of these deaths occur in low and middle-income countries of the world. Besides the need for a cost-effective solution possible, any program must also consider the societal realities for women living in communities while accessing healthcare services.

Community cervical screening camps face major roadblocks during follow-up evaluations and treatment. Women who attend cervical cancer screening largely remain untraceable primarily due to reasons related to childcare-related issues, cost of traveling, commuting long distances – or often due to unwarranted reasons such as the need to seek permission from the male partner, fear of cancer, deep-rooted stigma, prejudices.

The low-cost Visual Inspection with Acetic acid (VIA) remains a preferred choice in such regions where costs are a huge barrier to healthcare. But again, this remains a poor triage due to the dependency on the experience of those performing the colposcopy. HPV is the gold standard for cervical pre-cancer and cancer screening; however, the method requires high capital investments, and trained professionals and is complex. Hence, there exists an urgent need for a triage test that is reliable, low-cost, and easy to use.

Gyneye smart colposcope provides a complete cervical visualization.  Gyneye offers the highest level of cervical screening which is a state-of-art, CE-certified, hand-help and portable colposcope developed with a decade of field experience globally and designed to work in the lowest resource settings with localized multi-lingual support.

Gyneye’s application integration with telemedicine addresses the screening gaps and will make it easy and effective for virtual consultations with cervical cancer specialists from remote locations; the integration will empower the field team to deliver quickly with credibility by offering a single-window approach.

Using the VIA technique, Gyneye allows to capture of images of the cervix and assigns a SWEDE score to assess the risk of cancer. Our study has shown that SWEDE scores obtained by trained healthcare workers could offer an accurate cervical diagnosis.

Gyneye envisions using Artificial Intelligence as a tool to ease the dependency on cervical screening on experts and qualified resources. The smart device provides a simple, effective, and flexible means to conduct colposcopic examinations including risk assessment of cervical cancer, that are comparable to a traditional colposcope but much easier to use and implement. The workflow is designed to capture patient information, obtain consent, enter patient history, conduct an examination, and document your findings. You can review each image captured before you can save it to the patient record.